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               Treatment Alternatives to Obsessive Compulsive Disorder: An Evidence-Based Project 
  Katherine Oberwager, BA, RN  
   Mentor: Linda Samia, PhD, RN  
Purpose 
To answer the clinical PICOT question:  in adults with 
obsessive compulsive disorder (OCD), how does 
augmenting a selective serotonin reuptake inhibitor  
(SSRI) with N-acetyl-cysteine (NAC) compare to 
monotherapy with an SSRI in terms of symptom severity 
and to translate this evidence into practice.  
Background 
• OCD is a debilitating psychiatric diagnosis that 
affects 1-2% of the population4 
• The gold standard of treatment for OCD is selective-
serotonin-reuptake-inhibitor (SSRI)1 
• Up to 40% of OCD patients do not receive a clinical 
response from SSRIs3 
• The exact etiology of OCD is unknown, but 
literature has pointed to abnormalities in glutamate 
metabolism7 
• The Yale-Brown Obsessive Compulsive Scale (Y-
BOCS) is often used to assess severity of OCD 
symptoms1 
• NAC has been explored as a potential glutamate 
modulating therapy for OCD2 
• NAC is an over the counter medication that is 
affordable, accessible and has a low side effect 
profile2 
 
 
Evidence Synthesis 
• One RCT concluded NAC as a treatment adjunct to 
SSRI was more successful than placebo with SSRI (p 
< 0.001)¹ 
• Two systematic reviews concluded NAC is 
efficacious in as a treatment adjunct with SSRI for 
OCD based on three case reports and the 
aforementioned RCT3,6 
• One systematic review postulated that OCD may be 
heterogeneous in nature, which is why NAC may not 
be successful for glutamate-independent OCD based 
off of six retrospective case reports with various 
outcomes3 
• One RCT had non-significant results for overall Y-
BOCS score (p = 0.39), but significant results for 
compulsion subscale (p = 0.0013)5 
• All studies conclude that NAC is a very inexpensive, 
accessible medication, with low risk1,3,5,6,7 
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Proposed Evaluation 
References 
Databases: CINAHL, Cochrane, Central Register of 
Controlled Trials, EBSCO, Medline, Nursing and Allied 
Health Collection: Basic, PsychARTICLES, PsychINFO 
Keywords: obsessive compulsive disorder, OCD, n-
acetyl-cysteine, NAC 
Inclusion criteria: RTCs, systematic reviews,  
& case reports published between 2010-2017 
Exclusion criteria: articles not specific to OCD, articles 
not specific to NAC 
Final sample: Two double blind randomized placebo 
controlled trials, three systematic reviews 
Translation to Practice 
• Given the low side-effect profile, low cost, and 
accessibility, trialing OCD in treatment refractory 
OCD is appropriate  
• Trial NAC at 600mg BID for 1 month, and if 
tolerated, titrate up to 2400-3000mg/ day for eight 
weeks. If successful continue (YBOCS score <15 or 
patient report) , if unsuccessful (YBOCS score >15, 
patient report, discontinue  
Conclusion 
• The results are promising for utilizing NAC in OCD, 
but further research is needed with larger trials 
• Given the benign nature of NAC and potential 
efficacy it is appropriate to use in treatment 
refractory OCD, defined as at least two unsuccessful 
trials for patients who were treated with  two 
different first line medications 
 • Pilot trial in community mental health center using in 
patients with OCD who have failed two first line 
psychotropic agents  
• Biweekly check ins with patient to interview and 
administer Y-BOCS every visit for eight weeks 
• Present results to practice at prescriber meeting 
